$1.41
+0.31 (+28.18%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BCLI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 expanded access · 3 with posted results
Held by 0 tracked-famous managers · FINRA short interest 2.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)NCT06973629Change in the ALSFRS-R total score from baseline to Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Biological: Debamestrocel - MSC-NTF (NurOwn), Placebo | Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | 200 | 2028-11-01 | in 805 d | 2025-05-22 |
| Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSNCT03799718results2022-11-14Number of Participants With Treatment-emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: NurOwn (MSC-NTF cells) | Multiple Sclerosis, Chronic Progressive | 23 | 2021-03-11actual | — | 2023-12-04 |
| Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsNCT03280056results2024-02-29The Proportion of NurOwn® Treated Participants With a ≥1.25 Points/Month Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score at 28 Weeks Following the First Treatment as Compared to PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: NurOwn® (MSC-NTF cells) · Other: Placebo, Bone Marrow aspiration | Amyotrophic Lateral Sclerosis (ALS) | 196 | 2020-09-29actual | — | 2024-02-29 |
| Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSNCT02017912results2024-06-06Number of Patients With at Least One Treatment Emergent Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nurown MSC-NTF cells, Placebo | Amyotrophic Lateral Sclerosis (ALS) | 48 | Mar 2016actual | — | 2024-06-06 |
| Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01777646Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)Open-label · Treatment | Phase 2 | Completed | Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Amyotrophic Lateral Sclerosis | 14 | Sep 2014actual | — | 2018-03-08 |
| Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.NCT01051882Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: MSC-NTF cells transplantation (IM), MSC-NTF cells transplantation (IT) | Amyotrophic Lateral Sclerosis | 12 | Dec 2012actual | — | 2019-01-10 |
| Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALSNCT04681118expanded access | — | No longer available | Biological: NurOwn (MSC-NTF cells) | Amyotrophic Lateral Sclerosis | — | — | — | 2024-04-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19